Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hando (Shanghai) Biotechnology is a clinical-stage biotechnology company specializing in the development of innovative microbiome-based therapeutics. The company utilizes a proprietary platform to discover and develop live biotherapeutic products (LBPs) and microbial metabolites aimed at treating metabolic disorders, oncology, and immune-related diseases. Its lead candidate, HD-101, is currently being evaluated in Phase 1b/2a clinical trials for the treatment of type 2 diabetes and obesity. By targeting the gut-organ axis, Hando aims to provide novel treatment options for patients with chronic and refractory conditions. The company is backed by prominent venture capital firms and maintains a strong research and development presence in Shanghai's biotechnology hub.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hando.